Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene

Journal of Thoracic Oncology

Volumn 10, Issue 3, 2015, Pages 527-530

  Kimura, Madoka ^a   Endo, Hiroko ^a   Inoue, Takako ^a   Nishino, Kazumi ^a   Uchida, Junji ^a   Kumagai, Toru ^a   Kukita, Yoji ^a   Kato, Kikuya ^a   Imamura, Fumio ^a   Inoue, Masahiro ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HYBRID PROTEIN; MICROTUBULE ASSOCIATED PROTEIN LIKE 4 ANAPLASTIC LYMPHOMA KINASE FUSION PROTEIN; NEU DIFFERENTIATION FACTOR; PEMETREXED; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; NRG1 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSPNEA; FEMALE; FUSION GENE; HOSPITAL DISCHARGE; HUMAN; HYPERTRANSAMINASEMIA; IN VITRO STUDY; INTRACELLULAR SIGNALING; LIVER TOXICITY; LUNG ADENOCARCINOMA; LYMPHADENOPATHY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTIPLE PULMONARY NODULES; OXYGEN THERAPY; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR SPHEROID; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PROGNOSIS; TUMOR CELL CULTURE;

ADENOCARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEUREGULIN-1; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84938280491     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000381     Document Type: Article

References (8)

1. Choi YL, Soda M, Yamashita Y, ALK Lung Cancer Study Group EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010 363 1734 1739
2. Sasaki T, Koivunen J, Ogino A, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011 71 6051 6060
3. Katayama R, Khan TM, Benes C, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011 108 7535 7540
4. Tanizaki J, Okamoto I, Okabe T, Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 2012 18 6219 6226
5. Kondo J, Endo H, Okuyama H, Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci U S A 2011 108 6235 6240
6. Endo H, Okami J, Okuyama H, Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation. J Thorac Oncol 2013 8 131 139
7. Katayama R, Shaw AT, Khan TM, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012 4 120ra17
8. Okuyama H, Yoshida T, Endo H, Involvement of heregulin/HER3 in the primary culture of human urothelial cancer. J Urol 2013 190 302 310